Secondary Logo

Journal Logo

In May of this year, the FDA has approved 18F-flortaucipir (Tauvid; Avid Radiopharmaceuticals) for the detection of tau within the brain in patients with suspected tau related dementias. Just as there are 3 18F amyloid agents available, more tau agents should be expected.

In this issue, Oh and colleagues present "Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351". The point out that most first-generation tau PET tracers are limited for high off-target binding and detection of tau in non-Alzheimer disease (AD). They evaluated the potential clinical applications of 18F-PI-2620 as a novel PET tracer with a high binding affinity for tau deposition in AD and non-AD tauopathies in 26 participants diagnosed with either mild cognitive impairment, probable AD, frontotemporal dementia, or parkinsonism, as well as healthy controls. Participants underwent a 60- to 90-minute brain PET after 7 mci of 18F-PI-2620. Some participants had previous PET scans using 18F-THK-5351 or 18F-FP-CIT for dopamine transporter imaging.

All participants showed no increase in off-target binding in basal ganglia on 18F-PI-2620 PET, as compared with first-generation tau tracers. Aβ+ mild cognitive impairment or AD patients showed diverse cortical 18F-PI-2620 uptake in frontotemporoparietal cortex that correlated with participants' Mini-Mental Status Examination (ρ = −0.692, P = 0.013).

Participants with Aβ+ Parkinson disease with dementia and (Aβ unknown) primary progressive aphasia also showed increased 18F-PI-2620 uptakes in the frontotemporoparietal cortex. Patients with parkinsonism showed increased uptakes in the pallidum compared with Aβ− healthy controls (left: 1.41 ± 0.14 vs 1.04 ± 0.13, P = 0.014; right: 1.18 ± 0.16 vs 0.95 ± 0.07, P = 0.014).

Authors concluded that  18F-PI-2620 PET might be a sensitive tool to detect cortical tau deposits in patients with Aβ+ AD and Aβ+ non-AD tauopathies. This study also showed that "off-target" binding in the basal ganglia does not affect 18F-PI-2620.


Current Issue


Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351

Oh, Minyoung; Oh, Seung Jun; Lee, Sang Ju; More

Clinical Nuclear Medicine. 45(11):841-847, November 2020.




Show: